Keya Medical
AI for Smarter Healthcare
Keya Medical Raises $46M in Series D Round.
Keya Medical
Keya Medical is a medical technology manufacturer developing cardiovascular and neurological solutions using AI that enable healthcare delivery organizations to provide better patient care.
Since 2016, the company has combined advanced deep learning algorithms with other technologies to provide accurate diagnosis and treatment solutions to medical institutions around the world.
Today, Keya Medical has partnered with over 200 healthcare systems around the world, and the company’s products are used in Chinese hospitals, coronary catheterization labs, and imaging centers.
DeepVessel FFR
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
DeepVessel FFR Approved for Clinical Use in China
On January 15, 2020, the National Medical Products Administration (NMPA) in China issued the registration certificate approving DeepVessel FFR for clinical use.
CuraRad® – ICH
Who do we work with
Healthcare Delivery
Keya Medical is committed to developing medical imaging AI solutions in collaboration with healthcare providers. Since 2016, we have worked with more than 200 hospitals around the world.
Payers
Keya Medical is continuing to develop new solutions to improve cardiovascular disease diagnosis and treatment. We invite payers to continue the conversation on how our solutions can create savings.
Investors
Keya Medical is funded by visionary investors who want to make a positive social impact and benefit from the potential expansion of medical AI.
Start a collaboration with Keya Medical
Latest News
Will New Value-based Care Regulations Spark Innovation?
On Jan. 19, two regulatory changes went into effect that intend to modernize the Physician Self-Referral Statute & the Anti-Kickback Statute, facilitating the shift to value-based care.
Keya Medical Raises $46M in Series D Round
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
EACVI Best of Imaging: Advances in Cardiac CT
EACVI Best of Imaging introduced the latest advances in cardiac CT, promoting a patient-centric, multi-modality approach to cardiovascular disease diagnosis.
